Precipitated Withdrawal following Emergency Department-initiated Buprenorphine: A Retrospective Study
Year: 2025
Type: article
Language: en
Topic: Opioid Use Disorder Treatment
Authors and affiliations:
raw_author_name: Ian Chiu
raw_affiliation_strings: Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD (KD, DBG, BS, RGW)
Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD (MP)
RGW received research funding from Becton, Dickinson, and Company; Roche Diagnostics; Global Blood Therapeutics, Inc.; Novartis Pharmaceuticals; Egetis Therapeutics AB; EndPoint Health, Inc.; CSL Behring; and Pfizer Inc. He has received research funding from CoapTech, LLC through an NIH/NIDDK grant (R44DK115325). He has received research support in the form of equipment and supplies from Cepheid and Eldon Biologicals A/S. He is a paid consultant for the National Foundation of Emergency Medicine. He has no financial relationships with pharmaceutical companies that manufacture buprenorphine or related medications. The remaining authors report no conflicts of interest
Vanderbilt University School of Medicine, Nashville, TN (IC)
raw_author_name: Kristin Donegan
raw_affiliation_strings: Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD (KD, DBG, BS, RGW)
Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD (MP)
RGW received research funding from Becton, Dickinson, and Company; Roche Diagnostics; Global Blood Therapeutics, Inc.; Novartis Pharmaceuticals; Egetis Therapeutics AB; EndPoint Health, Inc.; CSL Behring; and Pfizer Inc. He has received research funding from CoapTech, LLC through an NIH/NIDDK grant (R44DK115325). He has received research support in the form of equipment and supplies from Cepheid and Eldon Biologicals A/S. He is a paid consultant for the National Foundation of Emergency Medicine. He has no financial relationships with pharmaceutical companies that manufacture buprenorphine or related medications. The remaining authors report no conflicts of interest
Vanderbilt University School of Medicine, Nashville, TN (IC)
raw_author_name: Daniel B. Gingold
raw_affiliation_strings: Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD (KD, DBG, BS, RGW)
Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD (MP)
RGW received research funding from Becton, Dickinson, and Company; Roche Diagnostics; Global Blood Therapeutics, Inc.; Novartis Pharmaceuticals; Egetis Therapeutics AB; EndPoint Health, Inc.; CSL Behring; and Pfizer Inc. He has received research funding from CoapTech, LLC through an NIH/NIDDK grant (R44DK115325). He has received research support in the form of equipment and supplies from Cepheid and Eldon Biologicals A/S. He is a paid consultant for the National Foundation of Emergency Medicine. He has no financial relationships with pharmaceutical companies that manufacture buprenorphine or related medications. The remaining authors report no conflicts of interest
Vanderbilt University School of Medicine, Nashville, TN (IC)
raw_author_name: Matthew Poremba
raw_affiliation_strings: Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD (KD, DBG, BS, RGW)
Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD (MP)
RGW received research funding from Becton, Dickinson, and Company; Roche Diagnostics; Global Blood Therapeutics, Inc.; Novartis Pharmaceuticals; Egetis Therapeutics AB; EndPoint Health, Inc.; CSL Behring; and Pfizer Inc. He has received research funding from CoapTech, LLC through an NIH/NIDDK grant (R44DK115325). He has received research support in the form of equipment and supplies from Cepheid and Eldon Biologicals A/S. He is a paid consultant for the National Foundation of Emergency Medicine. He has no financial relationships with pharmaceutical companies that manufacture buprenorphine or related medications. The remaining authors report no conflicts of interest
Vanderbilt University School of Medicine, Nashville, TN (IC)
raw_author_name: Benoit Stryckman
raw_affiliation_strings: Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD (KD, DBG, BS, RGW)
Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD (MP)
RGW received research funding from Becton, Dickinson, and Company; Roche Diagnostics; Global Blood Therapeutics, Inc.; Novartis Pharmaceuticals; Egetis Therapeutics AB; EndPoint Health, Inc.; CSL Behring; and Pfizer Inc. He has received research funding from CoapTech, LLC through an NIH/NIDDK grant (R44DK115325). He has received research support in the form of equipment and supplies from Cepheid and Eldon Biologicals A/S. He is a paid consultant for the National Foundation of Emergency Medicine. He has no financial relationships with pharmaceutical companies that manufacture buprenorphine or related medications. The remaining authors report no conflicts of interest
Vanderbilt University School of Medicine, Nashville, TN (IC)
raw_author_name: Richard Gentry Wilkerson